Diabetes & Obesity

5th September, A/Prof Chee L Khoo and A/Prof Shannon Lin Diabetes-related sarcopenia, characterised by the loss of muscle mass, strength, and function in people with diabetes, is an emerging but under-recognised complication associated with falls, frailty, hospitalisations, and reduced quality of life. I am working closely with researchers at the University of Technology Sydney (UTS) […]

29th August 2026, A/Prof Chee L Khoo The European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause recommend that a holistic approach is taken for women during perimenopause and menopause, not having a sole focus on hormone replacement therapy (HRT)/ menopausal hormone therapy (MHT) (1). It recognised that […]

28th August 2026, A/Prof Chee L Khoo Atherosclerotic cardiovascular disease (ASCVD) is considered an inflammatory condition. Not only is inflammation central to the initiation of ASCVD, it is also responsible for the progression as well as the destabilisation of atherosclerotic plaque leading to ischaemia. This is in addition to the other well known risk factors […]

13th August 2026, A/Prof Chee L Khoo We know (maybe better phrased – we think we know) that it is the amyloid-β (Aβ) plaques that are a key driver of pathological processes in Alzheimer’s disease (AD) (1,2).  Targeting the Aβ should then prevent or at the very least delay the progression of the dementia. The […]

25th July 2026, A/Prof Chee L Khoo We know that 55-65% patients with type 2 diabetes (T2D) have metabolic dysfunction associated fatty liver disease (MAFLD) (1). We also know that 28% of patients with MAFLD will develop T2D if not already present by the time MAFLD is detected (2). There is emerging evidence that there […]

30th June 2026, A/Prof Chee L Khoo We have waited for a very long time. We only have one second generation long-acting basal insulin even though degludec have been available overseas for ≥ 10 years now. Insulin degludec (iDeg), in combination with a prandial insulin (insulin aspart) has been available in Australia as Ryzodeg® since […]

28th June 2026, A/Prof Chee L Khoo It’s all over the news. Teplizumab (Tzield) has just been approved by the Australian Therapeutic Goods Administration (TGA) delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus (1). Wow. […]

10th June 2026, A/Prof Chee L Khoo We know that if a woman developed gestational diabetes mellitus (GDM), the risk of development of type 2 diabetes (T2D) later in life increases by 4-10 times. We also know that the same woman also have higher risk of developing elements of cardiovascular disease (CVD) including hypertension, atherosclerotic […]

23rd May 2026, A/Prof Chee L Khoo We all know about the causal association between the so called bad cholesterol, LDL-cholesterol (LDL-C) and atherosclerotic cardiovascular disease (ASCVD). There are suggestions that apolipoprotein B (apoB) levels might be a better reflection of atherosclerotic burden. There is now emerging consensus that relying on particle number whether with […]

25th April 2026, A/Prof Chee L Khoo When we think about diabetes, we think about the shrinkage of beta cell mass and its inability to keep up with the insulin demand. We have lots of information of what the islet cells can or cannot do in diabetes but we don’t actually know much of pathogenesis […]

24th April 2026, A/Prof Chee L Khoo Australian and international guidelines recommend 150– 300 min of moderate physical activity (MPA), 75–150 min of vigorous physical activity (VPA), or a combination of both per week (1,2). Some people prefer slower but longer exercises while other prefer more intense for shorter periods of time. There is data […]